Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jenburkt Pharmaceuticals's FCF Margin % or its related term are showing as below:
NSE:JENBURPH'
s FCF Margin % Range Over the Past 10 Years
Min: 3.93 Med: 8.72 Max: 16.82
Current: 7.59
During the past 13 years, the highest FCF Margin % of Jenburkt Pharmaceuticals was 16.82%. The lowest was 3.93%. And the median was 8.72%.
NSE:JENBURPH's FCF Margin % is ranked better than 64.96% of 959
companies
in the Drug Manufacturers industry
Industry Median: 2.45
vs NSE:JENBURPH: 7.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jenburkt Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jenburkt Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jenburkt Pharmaceuticals (NSE:JENBURPH) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jenburkt Pharmaceuticals and its competitors. Over the past decade, Jenburkt Pharmaceuticals' FCF Margin % has ranged from 3.93 to 16.82. According to the industry distribution chart, Jenburkt Pharmaceuticals ranks #336 out of 959 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is Jenburkt Pharmaceuticals' FCF Margin % too high?
Jenburkt Pharmaceuticals' current FCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 3.93 to a high of 16.82. Based on the distribution chart, Jenburkt Pharmaceuticals ranks #336 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' FCF Margin % compare to ?
According to the Drug Manufacturers industry distribution chart, Jenburkt Pharmaceuticals ranks #336 out of 959 companies for FCF Margin %. This puts Jenburkt Pharmaceuticals in the upper half of its industry. The industry median FCF Margin % is 2.45. Historically, Jenburkt Pharmaceuticals' own FCF Margin % has ranged from 3.93 to 16.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jenburkt Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jenburkt Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (NSE:JENBURPH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,136.66, compared to a current price of ₹1,028.50 — trading 9.5% below its estimated fair value. The current FCF Margin % is 0.00%. Jenburkt Pharmaceuticals' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (NSE:JENBURPH), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jenburkt Pharmaceuticals (NSE:JENBURPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹1,028.50 is trading 9.5% below its estimated GF Value™ of ₹1,136.66.
GuruFocus considers Jenburkt Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:JENBURPH:
FCF Margin %: 0.00%
GF Value™: ₹1,136.66 vs. price of ₹1,028.50 (9.5% below fair value)
No single metric tells the full story. See the NSE:JENBURPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
70GF Score
Get the complete analysis for NSE:JENBURPH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JENBURPH has been successfully added to your 
